MVM invests in innovative healthcare companies. Our active portfolio companies are transforming the delivery of healthcare by enabling higher quality, cost-effective care in large, global markets.
Portfolio 18
| Date | Name | Website | Total Raised | Location |
| 17.03.2021 | eXmoor Pha... | exmoorpharma.com | $35M | United Sta... |
| 25.11.2020 | GT Medical... | gtmedtech.com | $299.4M | United Sta... |
| - | Woodcast | woodcast.fi | - | - |
| - | Patient Co... | patientconnect.co.uk | - | United Kin... |
| - | Alliance P... | alliancepharma.co.uk | - | United Kin... |
| - | Vertos Med... | vertosmed.com | $54M | United Sta... |
| - | eZono | ezono.com | $10M | Germany, T... |
| - | Biotherano... | biotheranostics.com | $32M | United Sta... |
| - | SkyCell AG | skycell.ch | $271.67M | Switzerlan... |
| - | Valneva | valneva.com | $112M | France, Pa... |
Show more
News 16
| Date | Title | Description |
| 17.03.2021 | MVM invests in eXmoor Pharma | eXmoor, the expert cell and gene therapy (CGT) services company (Bristol, England), has announced an initial investment of £12m ($17m) from specialist healthcare investment firm MVM Partners (“MVM”), to enable eXmoor’s ambitious expansion p... |
| 04.03.2021 | Hologic announces acquisition of Biotheranostics | Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has agreed to acquire Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metasta... |
| 05.01.2021 | MVM Winter 2020 Newsletter | Winter 2020 Newsletter _________________________________________________ MVM team news MVM invests in Paragon 28 MVM invests in GT Medical SkyCell joins Abu Dhabi and Etihad to form the Hope Consortium Valneva agrees to provide 190 mil... |
| 25.11.2020 | MVM invests in GT Medical | GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced it has raised $16 million in a Series B financing led by MVM Partners with participation from existing investors MedTec... |
| 15.09.2020 | Valneva announces major COVID-19 vaccine partnership with UK government | - UK Government has secured supply of 60 million doses at a cost of €470 million with options over another 130 million doses between 2022 and 2025 - UK Government invests in Valneva’s manufacturing facility in Livingston, Scotland, to supp... |
| 10.09.2020 | MVM Summer 2020 Newsletter | Summer 2020 Newsletter ________________________________________ MVM team news MVM invests in MDxHealth MVM invests in SkyCell Valneva partners Lyme disease vaccine with Pfizer MVM sees rebound in medical procedure volumes _____________... |
| - | Valneva confirms participation in UK government COVID-19 vaccine response program | Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today confirmed its participation in the UK government COVID-19 vaccine response program. Valneva has reached agreement in principle wit... |
| - | Vertos MOTION study enrollment complete | Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), today announced the completion of enrollment in its nationwide, multicenter MOTION Study of its mild® Procedure.... |
| - | Valneva and Pfizer announce collaboration on Lyme Disease vaccine, VLA-15 | Valneva SE (“Valneva”), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies. V... |
| - | MVM Partners LLP Closes Fund V | MVM Partners today announced the closing of a $325 million healthcare fund, MVM V. MVM has been investing in high growth healthcare businesses since 1997 and this latest fund, MVM V, will continue this broad, global, investment remit with ... |
Show more
Mentions in press and media 18
| Date | Title | Description |
| 10.07.2026 | Neurent Medical Raises €62.5 million in Oversubscribed Series C Financing | Neurent Medical, the pioneer behind NEUROMARK®, an innovative, minimally invasive solution to treat chronic rhinitis, today announced the successful close of its oversubscribed Series C financing, raising €62.5 million ($74 million) to driv... |
| 16.06.2026 | GT Medical Technologies Secures $100M to Revolutionize Brain Tumor Treatment | GT Medical Technologies secured $100 million in oversubscribed Series E funding. Viking Global Investors led the round. These funds will fuel aggressive commercial expansion and advance critical clinical trials. The company's innovative Gam... |
| 11.06.2026 | GT Medical Technologies Raises $100 Million Series E Financing To Advance Brain Tumor Treatment Platform | GT Medical Technologies announced the completion of an oversubscribed $100 million Series E financing round led by new investor Viking Global Investors, with participation from existing investors including MVM Partners, Gilde Healthcare, Ev... |
| 09.06.2026 | GT Medical Technologies Raises $100M in Series E Funding | GT Medical Technologies, Inc., a Tampa, AZ-based medical device company dedicated to improving the lives of patients with brain tumors, raised $100M in Series E funding. The round was led by Viking Global Investors with participation from e... |
| 02.09.2025 | ProVerum: $80 Million Series B Raised For Advancing BPH Treatments | ProVerum Limited is a company that has made significant strides with its development of the ProVee System, a minimally invasive solution specifically designed for treating benign prostatic hyperplasia (BPH). Recently, the company announced ... |
| 28.02.2025 | VitalConnect Secures $100 Million to Propel Cardiac Monitoring Innovation | VitalConnect is on the rise. The San Jose-based company, a titan in biosensor technology, has just secured $100 million in funding. This infusion of capital comes from a mix of equity and debt financing. The new player in this financial gam... |
| 26.02.2025 | VitalConnect: Ambulatory Cardiac Monitoring Company Raises $100 Million | VitalConnect, a biosensor technology leader specializing in ambulatory cardiac monitoring, announced the closing of $100 million in financing through a combination of equity and debt capital. The equity funding was led by new investor Ally ... |
| 19.02.2025 | VitalConnect Raises $100M in Funding | VitalConnect, a San Jose, CA-based biosensor technology company, raised $100M in funding through a combination of equity and debt capital. The equity financing was led by new investor Ally Bridge Group, with participation from existing inve... |
| 26.01.2024 | Global healthcare VC firm invests $30m in icotec | Based in Altstätten (St. Gallen ), icotec develops and produces carbon-fiber-reinforced implants for spine tumor stabilization, allowing for the most accurate and safe radiation therapy due to artefact-free imaging. Their proprietary techn... |
| 11.02.2022 | As it prepares to join EQT, Life Science Partners surpasses €1B investment mark | Just a few months ago, the European investment firm Life Science Partners announced that it would be bought out by the private investment group EQT, a VC firm with more than $2.5 billion under management. Friday, it revealed that it has sur... |
Show more